Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
ESC Heart Failure|May 7, 2021
Design and rationale of the EMPA-VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failureMoritz J Hundertmark, Olorunsola F Agbaje, Ruth Coleman, et al.
Circulation. Cardiovascular Imaging|July 9, 2013
Myocardial steatosis and left ventricular contractile dysfunction in patients with severe aortic stenosisMasliza Mahmod, Sacha Bull, Joseph J Suttie, et al.
European Heart Journal|September 23, 2015
Cardiac energetics, oxygenation, and perfusion during increased workload in patients with type 2 diabetes mellitusEylem Levelt, Christopher T Rodgers, William T Clarke, et al.
Eclinicalmedicine|October 25, 2021
Symptom Persistence Despite Improvement in Cardiopulmonary Health - Insights from longitudinal CMR, CPET and lung function testing post-COVID-19Mark Philip Cassar, Elizabeth M Tunnicliffe, Nayia Petousi, et al.
ESC Heart Failure|October 27, 2024
Considerations for drug trials in hypertrophic cardiomyopathyJohn P Farrant, Matthias Schmitt, Anna B Reid, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|March 20, 2024
Metabolic profiling of aortic stenosis and hypertrophic cardiomyopathy identifies mechanistic contrasts in substrate utilizationNikhil Pal, Animesh Acharjee, Zsuzsanna Ament, et al.
Heart (British Cardiac Society)|May 3, 2023
Rationale and design of a randomised trial of trientine in patients with hypertrophic cardiomyopathyJohn Farrant, Susanna Dodd, Carly Vaughan, et al.
Circulation|April 18, 2023
Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION TrialMoritz J Hundertmark, Amanda Adler, Charalambos Antoniades, et al.
European Heart Journal. Digital Health|July 31, 2024
Hypertrophic cardiomyopathy detection with artificial intelligence electrocardiography in international cohorts: an external validation studyKonstantinos C Siontis, Mikolaj A Wieczorek, Maren Maanja, et al.
ESC Heart Failure|June 23, 2018
Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3-left ventricular hypertrophy (Beta3-LVH)Anne-Catherine Pouleur, Stefan Anker, Dulce Brito, et al.
Pageof 6